MedTrace Logo

Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01472991 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2013-04-30

No results posted yet for this study

Summary

Study is to assess if TC-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of ADHD over a 4-week treatment period.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

TC-5619-238 5mg

TC-5619-238 5mg capsule taken once daily for 4 weeks

DRUG

TC-5619-238 25mg

TC-5619-238 25mg capsules taken once daily for 4 weeks

DRUG

Placebo

Placebo capsules will be taken once daily for 4 weeks

Sponsors & Collaborators

  • Targacept Inc.

    lead INDUSTRY

Principal Investigators

  • Timothy Wilens, MD · Clinical Trials Network & Institute, Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01472991 on ClinicalTrials.gov